TACR1 and neoplasm: These studies highlight the potential of the NK-1R antagonist aprepitant to decrease tumor volume and the expression of Ki-67, as well as rationalize the potential need for future phase I and II clinical trials to be conducted to assess the potential of NK-1R antagonists, such as aprepitant, in osteosarcoma.